

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (Rev. 2-32)  <b>Information Disclosure Statement by Applicant</b>  (Use several sheets if necessary)	ATTY. DOCKET NO. UPAP-0495	SERIAL NO 09/980,762
	APPLICANT D. Weiner et al.	
	FILING DATE September 3, 2002	GROUP 1644

## U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
JO	4,722,848	02/02/88	Paoletti et al.			
	4,736,866	04/12/88	Leder et al			
	4,873,191	10/10/89	Wagner et al.			
	4,945,050	01/31/90	Sanford et al.			
	5,017,487	05/21/91	Stunnenberg et al.			
	5,036,006	07/30/91	Sanford et al.			
	5,077,044	12/31/91	Stocker			
	5,110,587	05/05/92	Paoletti et al.			
	5,112,749	05/12/92	Brey, III et al.			
	5,174,993	12/29/92	Paoletti			
	5,223,424	06/29/93	Cochran et al.			
	5,225,336	07/06/93	Paoletti et al.			
	5,240,703	08/31/93	Cochran			
	5,242,829	09/07/93	Panicali et al.			
	5,294,441	03/15/94	Curtiss			
	5,294,548	03/15/94	Curtiss			
	5,310,668	05/10/94	Ellis et al.			
	5,387,744	02/07/95	Curtiss III et al.			
	5,389,368	02/14/95	Curtiss III			
	5,424,065	06/13/95	Curtiss III et al.			
	5,451,499	09/19/95	Cochran			
	5,453,364	09/26/95	Paoletti			
	5,462,734	10/31/95	Letchworth III et al.			
	5,470,734	11/28/95	Sondermeijer et al.			
	5,482,713	01/09/96	Paoletti			
	5,589,466	12/31/96	Felgher et al.			
	5,593,972	01/14/97	Weiner et al.			
	5,739,118	04/14/98	Carrano et al.			
	5,830,876	11/03/98	Weiner et al.			
	5,837,533	11/17/98	Boutin			
JO	5,942,607	08/24/99	Freeman et al.			

RECEIVED  
APR 28 2003  
TECH CENTER 1605/200

Examiner	<i>Ilija Ouspenski</i>	Date Considered	<i>4/4/2006</i>
----------	------------------------	-----------------	-----------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (Rev. 2-32)  <b>Information Disclosure Statement by Applicant</b>  (Use several sheets if necessary)	ATTY. DOCKET NO. UPAP-0495	SERIAL NO 09/980,762
	APPLICANT D. Weiner et al.	
	FILING DATE September 3, 2002	GROUP

## FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES   NO
JO	90/11092	10/04/90	WO			
	94/16737	08/04/94	WO			
	93/17706	09/16/93	WO			
	96/10038	04/04/96	WO			
	95/26718	10/12/95	WO			
	93/23552	11/25/93	WO			

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

	1.	International search report for PCT/US88/11310 dated October 17, 2000.
	2.	Selvakumar et al., "Genomic Organization and Chromosomal Location of the Human Gene Encoding The B-Lymphocyte Activation Antigen B7," <u>PubMed</u> , 1992, abstract only.
	3.	Lanier et al., "CD80 (B7) and CD86 (B70) Provide Similar Costimulatory Signals for T Cell Proliferation, Cytokine Production, and Generation of CTL," <u>PubMed</u> , 1995, abstract only.
	4.	Azuma et al., "B70 Antigen is a Second Ligand for CTLA-4 and CD28," <u>Nature</u> , November 8, 1993, Vol. 366, pp. 76-79.
	5.	Freeman et al., "Structure, Expression, and T Cell Costimulatory Activity of the Murine Homolog of the Human B Lymphocyte Activation Antigen B7," <u>J. Exp. Med.</u> , September 1991, Vol. 174, pp. 625-631.
	6.	Freeman et al., "A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells," <u>The Journal of Immunology</u> , July 11, 1989, Vol. 143, pp. 2714-2722.
	7.	Howell et al., "Limited T-Cell Receptor $\beta$ -Chain Heterogeneity Among Interleukin 2 Receptor-Positive Synovial T Cells Suggests a Role for Superantigen in Rheumatoid Arthritis," <u>Proc. Natl. Acad. Sci.</u> , December 1991, Vol. 88, pp. 10921-10925.
	8.	Kim et al., "Engineering of In Vivo Immune Responses to DNA Immunization Via Codelivery of Costimulatory Molecule Genes," <u>Nature Biotechnology</u> , July 15, 1997, Vol. 15, pp. 641-646.
	9.	Oksenberg et al., "Limited Heterogeneity of Rearranged T-Cell Receptor V $\alpha$ Transcripts in Brains of Multiple Sclerosis Patients," <u>Letters to Nature</u> , May 24, 1990, Vol. 345, pp. 344-346.
	10.	Paliard et al., "Evidence for the Effects of a Superantigen in Rheumatoid Arthritis," <u>Science</u> , July 19, 1991, Vol. 253, pp. 325-329.
	11.	Linsley et al., "Human B7-1 (CD80) and B7-2 (CD86) Bind with Similar Avidities but Distinct Kinetics to CD28 and CTLA-4 Receptors," <u>PubMed</u> , December 1994, Vol. 1, No. 9, abstract only
	12.	W. Williams, "Restricted Heterogeneity of T Cell Receptor Transcripts in Rheumatoid Synovium," <u>J. Clin. Invest.</u> , August 1992, Vol. 90, pp. 326-333.
	13.	Chaudhary et al., "A Rapid Method of Cloning Functional Variable-Region Antibody Genes in <i>Escherichia Coli</i> as Single-Chain Immunotoxins," <u>Proc. Natl. Acad. Sci.</u> , February 1990, Vol. 87, pp. 1066-1070
JO	14.	K. Wucherpfennig, et al., "Shared Human T Cell Receptor V $\beta$ Usage to Immunodominant Regions Of Myelin Basic Protein," <u>Science</u> , 1990, Vol. 248, pp. 1016-1019.

Examiner <i>Ilian Ouspenski</i>	Date Considered <i>4/4/2006</i>
---------------------------------	---------------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/980,762
				Filing Date	September 3, 2002
				First Named Inventor	David B. Weiner
				Art Unit	Not Yet Determined - 1644
				Examiner Name	Not Yet Determined J. Duszynski
Sheet	1	of	2	Attorney Docket Number	UPAP0013-100

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>o</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
JO		WO 96/11279	04/18/96	The Government of the United States of America		
JO		WO 96/40915	12/19/96	Dana-Farber Cancer Institute		
JO		WO 95/03408	02/02/95	Dana-Farber Cancer Institute		

Examiner Signature	<i>J. Duszynski</i>	Date Considered	4/6/2006
-----------------------	---------------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	09/980,762
Filing Date	September 3, 2002
First Named Inventor	David B. Weiner
Group Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket Number	UPAP0013-100

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
IO		<del>European Search Report dated June 18, 2003, Application No. 00926416</del>	
		Gerstmayer et al., "Costimulation of T-cell Proliferation by a Chimeric B7-Antibody Fusion Protein," <u>Cancer Immunol Immunother</u> , Vol. 45, Nos. 3-4, pp. 156-158 (1997).	
		Fargeas et al., "Identification of Residues in the V Domain of CD80 (B7-1) Implicated in Functional Interactions with CD28 and CTLA4," <u>Journal of Experimental Medicine</u> , September 1, 1995, Tokyo, JP, vol. 182, pages 667-675.	
		Peach et al., "Both Extracellular Immunoglobulin-like Domains of CD80 Contain Residues Critical for Binding T-Cell Surface Receptors CTLA-4 and CD28" <u>Journal of Biological Chemistry</u> , American Society of Biological Chemists, September 8, 1995, Baltimore, MD, vol. 270, No. 36, page 1182, line 1-10, page 21185-21188	
IO		Inobe et al., "Identification of an Alternatively Spliced Form of the Murine Homologue of B7," <u>Biochemical and Biophysical Research Communications</u> , Academic Press Inc., April 15, 1994, Orlando, FL, vol. 200, no. 1, page 446.	

Examiner Signature	<i>Lina Oursperschi</i>	Date Considered	4/4/2006
-----------------------	-------------------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.